ArticleEuropean journal of nuclear medicine and molecular imaging2019
Relationship between the expression of PD-1/PD-L1 and
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- Association of SUVmax and never-smoker/never- or minimally-drinker history with PD-L1 expression in resected oral squamous cell carcinoma: a nodal-status-stratified analysis.Annals of nuclear medicine · 2026Article
- Comparison of pre-treatmentEuropean radiology · 2026Article
- Nuclear medicine in predicting hepatocellular carcinoma response.Nuclear medicine communications · 2026Review
- Assessment of tertiary lymphoid structures viaCancer immunology, immunotherapy : CII · 2025Article
- Pseudoprogression Shown onMolecular imaging and radionuclide therapy · 2025Article
- Performance ofiScience · 2024Article
- The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.Japanese journal of radiology · 2024Review
- Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors.Current cancer drug targets · 2024Review
- Radiogenomics: a key component of precision cancer medicine.British journal of cancer · 2023Review
- Relationship between the expression of PD-L1 andBritish journal of cancer · 2023Article
- Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.European journal of nuclear medicine and molecular imaging · 2023Article
- Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023Review
- Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation.BMC cancer · 2023Article
- Retrospective Analysis of the Predictive Value ofDiagnostics (Basel, Switzerland) · 2023Article
- Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.International journal of molecular sciences · 2022Review
- Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.Cancers · 2022Review
- eIF6 is potential diagnostic and prognostic biomarker that associated withJournal of translational medicine · 2022Article
- Pretreatment Metabolic Parameters Measured byFrontiers in oncology · 2022Article
- PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.Frontiers in immunology · 2022Review
- The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmunotherapy aimed at inhibiting the PD-1/PD-L1 immune checkpoint has been approved and used successfully for the treatment of bladder cancer. The identification of markers predictive of response to immune checkpoint inhibitors is critical to advancing the success of this therapy.
methodsA retrospective analysis was performed in 63 patients with bladder cancer who had undergone
resultsSUVmax was significantly higher in PD-1-positive patients than in PD-1-negative patients (33.0 ± 13.9 and 19.6 ± 14.2, respectively; P = 0.032), and in PD-L1-positive patients than in PD-L1-negative patients (29.1 ± 15.6 and 15.8 ± 11.4, respectively; P < 0.0001). In a multivariate analysis SUVmax was significantly associated with both PD-1 expression and PD-L1 expression (P = 0.021 and P = 0.003, respectively). Using a SUVmax cut-off value of 22.7, PD-1 status and PD-L1 status could be predicted with accuracies of 71.4% and 77.8%, respectively.
conclusionHigher
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.